TRCT
AARD

Tower Research Capital (TRC)’s Aardvark Therapeutics AARD Stock Holding History

Tower Research Capital (TRC)’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4K Sell
2,501
-2,966
-54% -$13.9K ﹤0.01% 3815
2026
Q1 		$20.6K Buy
5,467
+4,656
+574% +$48.3K ﹤0.01% 3459
2025
Q4 		$10.6K Sell
811
-374
-32% -$4.67K ﹤0.01% 3729
2025
Q3 		$15.7K Sell
1,185
-83
-7% -$936 ﹤0.01% 3524
2025
Q2 		$17.1K Buy
+1,268
New +$13.1K ﹤0.01% 3757

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Tower Research Capital (TRC)'s AARD Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Aardvark Therapeutics (AARD) stake by 54% in Q2 2026, selling an estimated $13.9K and leaving 2,501 shares worth $14.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3815.

Tower Research Capital (TRC) first reported a position in AARD in Q2 2025 and has held it in 5 quarters since. The position peaked at $20.6K in Q1 2026. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Tower Research Capital (TRC) held 2,501 shares of Aardvark Therapeutics worth $14.4K as of Q2 2026.
  • Tower Research Capital (TRC) sold 2,966 Aardvark Therapeutics shares in Q2 2026, an estimated $13.9K.
  • Aardvark Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3815 holding.
  • Tower Research Capital (TRC) first reported a position in Aardvark Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Tower Research Capital (TRC)'s Aardvark Therapeutics position peaked at $20.6K in Q1 2026.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.